Our Science

A rapid discovery platform

Identify KIPS (Kinase Privileged Scaffolds) and use Multicomponent rapid chemical synthesis reactions to generate novel highly effective kinase inhibitors.

Learn More

Tailored drug design with molecular precision

Highly versatile system. Straightforward synthesis, custom medicinal Chemistry to achieve drug-like properties and rational design of chemical matter to achieve desired selectivity

Learn More

Rational selectivity

Optimize target specificity of compounds based both on the clinical landscape of evolving mutations in the primary target and ‘collaborating’ kinases that confer resistance.

Learn more

A proprietary kinase inhibitor library

Using our scientific expertise and proprietary technology we have generated a library of compounds that includes many best-in-class drug candidates. Our discovery engine constantly expands and refines this library.

Learn More

A rapid discovery platform

Kinase Privileged Scaffolds (KIPS) are identified by screening classes of compounds with specific activity and selectivity

Multicomponent chemical synthesis reactions are used as a rapid chemistry platform the generate libraries of compounds

Tailored drug design with molecular precision

Once lead compounds are identified we apply our proprietary medicinal chemistry pipeline to generate compounds with optimal drug-like properties.

This will increase the chances of bio-availability and reduce the risk of unwanted side effects.

Rational selectivity

Screen compounds which can potently inhibit both the primary target and drug resistant mutations that arise during treatment.

Focus on compounds that also target collaborating kinases that contribute to disease progression.

A proprietary kinase inhibitor library

Using our scientific expertise and proprietary technology we have generated a library of compounds that includes many best-in-class drug candidates.

Our discovery engine constantly expands and refines this library.

Publications

Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines

Identification of New FLT3 Inhibitors That Potently Inhibit AML Cell Lines via an Azo Click-It/Staple-It Approach

Alkynylnicotinamide-based compounds as ABL1 inhibitors with potent activities against drug-resistant CML harboring ABL1(T315I) mutant kinase.

Elizabeth A. Larocquea, Dr. N Nagannaa, Clement Opoku-Temenga,b, Alyssa M. Lambrechta, and Prof. Dr. Herman O. Sintima

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6312196/